Recombinant IL2RA (Daclizumab Biosimilar) antibody
Quick Overview for Recombinant IL2RA (Daclizumab Biosimilar) antibody (ABIN7795104)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Daclizumab Biosimilar, CD25 Monoclonal Antibody
-
Characteristics
- Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90 % ) and murine (10 %) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD25
-
-
anti-IL2RA (Daclizumab Biosimilar) antibody
Reactivity: Human, Cynomolgus, Rhesus Monkey FACS, BR Host: Rabbit Chimeric unconjugated Recombinant Antibody
anti-IL2RA (Daclizumab Biosimilar) antibodyReactivity: Human, Cynomolgus, Rhesus Monkey FACS, BR Host: Human Monoclonal unconjugated Recombinant Antibody
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL2RA (Daclizumab Biosimilar)
-
Alternative Name
- Daclizumab Biosimilar
-
Target Type
- Biosimilar
Target
-
